Onset Age is Associated with Outcome of Radioiodine Therapy in Graves' Disease

Abstract

Abstract. Controversy remains regarding the optimal dose calculation with radioiodine therapy for patients with Graves' disease. Here, we focused our analysis on data concerning the patient's pretreatment background, an empirically set dose of radioiodine and the post-treatment thyroid function, and investigated those factors that affected the outcome. The subjects consisted of 38 patients diagnosed as having Graves' disease. All patients were hospitalized to undertake radioiodine therapy between 1989 and 1998 at our hospital. At the follow-up periods of 6-, 12-, and 36-months after therapy, we divided the patients into two groups: one group those who had hypothyroid function, and the other those who had normal or hyperthyroid function. At 6-and 12-months, 50% of the patients belonged to the hypothyroid function group, whereas at 36-months, 55% of them had hypothyroid function. Logistic regression analysis, with the objective variable being the post-treatment hypothyroidism after 12 months, revealed that the significant factor was the onset age. We suggested that the age at onset should be considered in patients with Graves' disease to determine the optional radioiodine dose for the therapy.

High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease

“…Post-RIT thyroid function outcome did not correlate with various factors such as gender, age at diagnosis, disease duration, anti-thyroid drug used, FT 4 serum levels, TSH levels, differently from other reports [8,14,15,17,[20][21][22]32]. Besides, relevant information can be obtained with TRAb, and its routine dosage is not available in our institution.…”

“…Various authors have reported a lower success rate of RIT in younger and male patients, in patients with more severe hyperthyroidism [14,15], in patients with large goitre [15], with high serum TRAb levels [16], in younger patients at diagnosis [17] with low or high pre-treatment thyroid radioiodide uptake [7,15,18]. Furthermore, some authors believe that the use of thyrostatic drugs during RIT would have a radioprotective effect to the thyroid reducing treatment success [8,[19][20][21][22], while other authors disagree [20,23].…”

Predictive Factors of Outcomes in Personalized Radioactive Iodine (131I) Treatment for Graves’ Disease

“…In our study and consistent with several other reports, 7,[9][10][11][12][13]24 we also found that other clinical parameters, such as age, sex and pre-RIT serum levels of TSH, FT4 or FT3 had no influence on outcomes. The main weakness of this study is the lack of data on thyroid autoantibodies titers, especially TRAb levels.…”

Assays for Thyroid-stimulating Antibodies and Thyrotropin-binding Inhibitory Immunoglobulins in Children with Graves' Disease

“…However, it is reported that TSAb was correlated with the severity of ophthalmopathy in adult Graves' disease [28,29]. The clinical and biological findings of Graves' disease, including ophthalmopathy, are different with age [4,24,25,27,[30][31][32][33], and so it is possible that this difference might be due to age. However, we examined only the presence of ophthalmopathy, and not its severity, hence further evaluation is needed.…”